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Immune escapeCytotoxic T lymphocyte responses to conserved proteins such as Gag within HIV- or SIV-infected hosts can
facilitate partial control of viremia. However, the utility of targeting variable viral proteins by CTL responses is
unclear. We studied CTL responses to regulatory and accessory proteins of SIV in pigtail macaques. The
regulatory and accessory proteins were the most commonly targeted proteins by CTL responses from pigtail
macaques. We identiﬁed 2 novel Tat-speciﬁc CTL responses that were both restricted by the Mane-A⁎10
allele. Viral escape at one of the Tat epitopes, KSA10, was slower in comparison to another Tat epitope KVA10.
The kinetics of escape of the KSA10 Tat epitope were more similar to an immunodominant KP9 Gag epitope
also restricted by Mane-A⁎10. Our results suggest that some regulatory or accessory CTL epitopes may be
useful targets for vaccination against HIV.
© 2009 Elsevier Inc. All rights reserved.Introduction
The quest for an HIV vaccine continues as scientists struggle to
understand how to generate effective, long-lasting immunity against
HIV. Despite decades of research several fundamental questions
remain unanswered. The HIV proteins to target in order to provide
optimal protection against HIV remain unclear. CD8+ T cell responses
clearly facilitate immune control of HIV/SIV (Jin et al., 1999; Koup et
al., 1994; Kuroda et al., 1999) but did not protect humans from HIV-1
infection in a recent Adenovirus vector vaccine trial (Buchbinder et al.,
2008; McElrath et al., 2008). It has been widely viewed that an
effective HIV vaccine would need to generate broad anti-HIV CD8+ T
cell responses likely targeting as many proteins as possible (Betts et
al., 1999; Chouquet et al., 2002). However, recent studies suggest that
there are signiﬁcant differences in the efﬁcacy of T cell immune
responses to individual HIV antigens with the occurrence of both
useful and potentially detrimental virus-speciﬁc T cell responses
(Kiepiela et al., 2007; Ngumbela et al., 2008). Gag-speciﬁc T cell
responses have been shown to be particularly efﬁcacious in control-
ling HIV viremia while Env-speciﬁc T cell responses appear to be less
helpful (Kiepiela et al., 2007; Masemola et al., 2004; Zhuang et al.,
2008). Similarly, differences in suppressive efﬁcacy of individual SIV
epitope-speciﬁc T cell lines have also been documented (Loffredo et
al., 2007; Loffredo et al., 2005). As yet, however, there is no clear
consensus regarding the optimal speciﬁcity and range of proteins thatll rights reserved.need to be targeted in order to establish long-term protection against
HIV. While there is general agreement on the usefulness of targeting
Gag antigens (Edwards et al., 2002; Masemola et al., 2004; Novitsky et
al., 2003), the utility of CD8+ T cells speciﬁc for other viral antigens
remains unclear.
Non-structural proteins of SIV and HIV-1 are also frequent targets
of CTL responses (Addo et al., 2001; Mothe et al., 2002). In the well-
characterized Indian rhesus macaque model of SIV infection, the
Mamu-A⁎01 allele restricts both an immunodominant Tat and Gag CTL
epitopes. However, the SL8 Tat epitope undergoes immune escape
early and appears to contribute little to immune control of SIV,
whereas the CM9 Gag tends to escape much later and is clearly
associated with enhanced immune control of SIV (Allen et al., 2002;
Allen et al., 2000; O'Connor et al., 2002b). Tat is a variable protein and
whether all Tat epitopes are unhelpful or only a subset is not clear.
In order to study the utility of CD8+ T cell responses against
individual viral proteins, we examined CD8+ T cell responses to SIV in
a cohort of 32 pigtail macaques from a recent peptide-pulsed blood
cell immunotherapy study (De Rose et al., 2008b). In that study we
found that inducing CD8+ T cell responses to SIV Gag alone was as
effective at controlling viremia as inducing T cell responses to all SIV
antigens. Furthermore, SIV Gag-speciﬁc CD8+ T cell responses were
superior to Env-speciﬁc CD8+ T cell responses at delaying SIV disease
progression (Peut and Kent, 2009). However, we now show that a
large proportion of animals recognized a pool of SIV regulatory and
accessory peptides. The majority of these responses were directed
against SIV Nef and Tat. SIV Tat-speciﬁc CD8+ T cell responses were
mapped to 2 novel epitopes restricted by the MHC class I Mane-A⁎10
allele. Sequencing across these Tat epitopes in the SIV infected animals
316 R.D. Mason et al. / Virology 388 (2009) 315–323revealed several mutations conferring escape from CTL in both Tat
epitopes. There was a clear difference in the rate of CTL escape
between the 2 Tat epitopes suggesting constraints in immune escape
at one of the Tat epitopes. Our results suggest vaccinating against
particular epitopes within some HIV regulatory/accessory proteins
may help contribute to subsequent viral control.
Results
Robust CD8+ T cell responses to SIV accessory and regulatory proteins
following acute infection
CD8 Tcell responses to HIV-1 accessory and regulatory proteins are
common in HIV-infected humans (Addo et al., 2002; Altfeld et al.,
2001) but the frequency of responses to similar accessory and
regulatory proteins in outbred pigtail macaques infected with SIV is
not known. When assessed across a large study of SIV-infected pigtail
macaques we found a combined pool of peptides spanning the 6
regulatory/accessory proteins were more commonly targeted than
Gag, Env or Pol proteins (Fig 1a). Eighteen out of thirty-two SIVmac251-
infected animals generated CD8+ T cell responses to a combined SIV
accessory and regulatory protein (RTNVVV) peptide pool 4 weeks post
infection (p.i.) (De Rose et al., 2008a). By comparison, SIV Gag-, Pol-
and Env-speciﬁc CD8+ T cell responses at the same timepoint were
observed in only 4,1 and 7 animals, respectively. By 14weeks p.i., 16, 4,
9 and 28 out of 32 animals had SIV Gag-, Pol-, Env- and RTNVVV-
speciﬁc CD8+ T cell responses, respectively. The SIV RTNVVV-speciﬁc
IFNγ CD8+ T cell responses ranged from 1–12% of total CD3+CD8+ T
cells. Responses to SIV proteins present in the vaccines (either Gag or
all SIV proteins) were overall higher in animals receiving those
vaccinations (Fig. 1a shows a breakdown of responses by vaccineFig.1. Speciﬁcity of CD8+ Tcell responses directed against SIV. a) Proportion of SIV-infected p
a combined pool of the 6 regulatory/accessory proteins at 4 (black) and 14 (grey) weeks
following 6-h stimulation of whole blood with pools of overlapping peptides spanning Rev, T
expressing the Mane-A⁎10 allele are noted below the graph.group), but the responses to the regulatory/accessory proteins were
common across all groups.
To determine which of the 6 regulatory/accessory proteins were
most commonly targeted by CD8 T cell responses, we mapped
responses to peptide pools spanning individual proteins in the 13
animals with responses to the combined pool exceeding 0.5% of CD8 T
cells (Fig. 1b). The frequency of responses to SIV regulatory/accessory
proteins was TatNNefNVif/VprNVpx/Rev. Intriguingly, we noted that
most animals targeting SIV Tat shared the MHC class I allele Mane-
A⁎10 suggesting the possibility that Mane-A⁎10-restricted a SIV Tat
CD8+ T cell epitope.
Identiﬁcation of SIV Tat CD8+ T cell epitopes
To facilitate further study of common SIV regulatory/accessory
protein speciﬁc CD8+ T cells we mapped SIV Nef- and Tat-speciﬁc
responses in multiple animals, ﬁrst to individual 15-mer peptides
within the overlapping peptides. Mapping of CD8+ T cell responses in
5 of the Nef responders revealed that the animals recognized 5
separate epitopes within 15-mer Nef peptides (Table 1). By contrast,
parallel epitope mapping of SIV Tat-speciﬁc CD8+ T cell responses
revealed that CTL responses toTat commonlymapped to 2 epitopes. Of
the 7 animals studied, 3 animals recognized the 15-mer peptide Tat
5429 (TPKKAKNTSSASNK), 2 animals recognized an epitope over-
lapping 15-mer peptides Tat 5435-6 (QPEKAKKETVEKAVA and
AKKETVEKAVATAPG) and one animal recognized both these epitopes.
Animal 8346 responded to an adjacent epitope within Tat peptide
5437 (TVEKAVATAPGLGR).
Since MHC class I molecules generally bind peptides between 8
and 11 amino acids long, we tested dilutions of overlapping peptides
of varying length by IFNγ ICS to determine the minimal optimal SIVigtail macaqueswith IFN-γ production by CD8+ Tcells in response to SIV Gag, Env, Pol or
post-SIV infection. b) CD8 T cell responses to individual accessory/regulatory proteins
at, Nef, Vif, Vpr and Vpx in individual pigtail macaques from 14 to 22 weeks p.i.. Animals
Table 1
SIV Nef and Tat peptides targeted by CD8+ T cells in SIV-infected pigtail macaques.
Animal Peptide SIV peptide sequence MHC class I Mane allele
A⁎03 A⁎10 B⁎02 B⁎10 B⁎11/22 B⁎12
8012 Nef 8606 RVPLRTMSYKLAIDM − − − − − −
8251 Nef 8611 EKGGLEGIYYSARRH − − − − − −
8680 Nef 8621 IRYPKTFGWLWKLVP − − − − − −
9017 Nef 8631 DPWGEVLAWKFDPTL − + − − − −
Nef 8632 EVLAWKFDPTLAYTY
9176 Nef 8639 SGLSEEEVRRRLTAR − + − − − −
8020 Tat 5429 TPKKAKANTSSASNK + + + +
8454 Tat 5429 TPKKAKANTSSASNK + + +
9017 Tat 5429 TPKKAKANTSSASNK + + + +
9021 Tat 5429 TPKKAKANTSSASNK + + +
8240 Tat 5435 QPEKAKKETVEKAVA − + − − − +
Tat 5436 AKKETVEKAVATAPG
9021 Tat 5435 QPEKAKKETVEKAVA + + − − − +
Tat 5436 AKKETVEKAVATAPG
9176 Tat 5435 QPEKAKKETVEKAVA − + − − − −
Tat 5436 AKKETVEKAVATAPG
8436 Tat 5437 TVEKAVATAPGLGR − − − − − −
317R.D. Mason et al. / Virology 388 (2009) 315–323Tat epitopes within the Tat 5429 and Tat 5435-6 15-mer peptides.
The 10mer peptide KKETVEKAVA (Tat114–123, KVA10) optimally
stimulated IFNγ production by CD8+ T cells in an SIV Tat 5435-6
responder (Fig. 2a). Based on the sequence similarity between Tat
KVA10 (KKETVEKAVA) and the Tat87–96 sequence KKAKANTSSA
(KSA10) within Tat 5429, we compared Tat KSA10 and additional
smaller peptides against the 15-mer peptide Tat 5429 at varying
concentrations by IFNγ ICS (Fig. 2b). As expected, Tat KSA10 stimulated
IFNγ production at lower concentrations than the other putative
epitope peptides tested as well as the 15-mer peptide Tat 5429
suggesting that KKAKANTSSA (Tat87–96, KSA10) was the minimal
optimal epitope recognized by Tat 5429 responders.
SIV Tat KSA10 and KVA10 CD8+ T cell epitopes are presented by
Mane-A⁎10
To determine the MHC restriction of SIV Tat KSA10- and KVA10-
speciﬁc CD8+ T cells, we compared MHC class I genotyping of pigtail
macaques responding to each epitope. Of the alleles typed for, only aFig. 2. Identiﬁcation of minimal optimal CD8+ T cell epitopes within SIV Tat and effect of esca
8-thru 11-mer synthetic peptides spanning amino acids (a) 114–123 and (b) 87–96 of SIV Ta
for optimal stimulation of SIV Tat-speciﬁc CD8+ T cells. The relative ability of synthetic pept
variant epitope sequences to stimulate CD8+ T cell responses was measured by IFNγ ICS onsingle shared MHC class I allele, Mane-A⁎10, was common to SIV Tat
KSA10 and KVA10 responders suggesting that both responses were
likely restricted by Mane-A⁎10 (Table 1). Further, we have previously
identiﬁed an immunodominantMane-A⁎10-restricted SIV Gag CD8+ T
cell epitope KP9 (Gag164–172, KKFGAEVVP) (Fernandez et al., 2005;
Smith et al., 2005b; Smith et al., 2005c). The shared N-terminus lysine
repeat sequence motif in SIV Gag KP9 and both SIV Tat KSA10 and
KVA10 epitopes further suggested that the two Tat CD8+ T cell
epitopes were also Mane-A⁎10-restricted. Since in vitro folding of
MHC I/peptide complexes is intolerant of extensions or truncations to
the optimal minimal peptide, we folded Tat KSA10 and KVA10
peptides with Mane-A⁎10 molecules in vitro. We successfully folded
both Mane-A⁎10/Tat KSA10 and Mane-A⁎10/Tat KVA10 tetramers
(not shown). We then used PE-labeled tetramers to stain PBMC
obtained at week 3 and 14 after SIV infection of 12 of the 13 Mane-
A⁎10+ animals from within the SIV infection study, including the
animals with strong responses to these peptides identiﬁed by the
earlier IFNγ ICS study (Table 2). Tetramer staining with Mane-A⁎10
folded around either SIV Tat KSA10 or SIV Tat KVA10 peptidespe mutations. Whole blood was stimulated with varying concentrations of overlapping
t and stained for intracellular IFNγ in order to identify the minimum sequence required
ides corresponding to (c) KVA10 and (d) KSA10 wild-type peptides and corresponding
whole blood following in vitro re-stimulation with a range of peptide concentrations.
Fig. 3. Avidity of CD8 T cells for KSA10, KVA10, and KP9 epitopes. PBMC from animal
8240 obtained 14 weeks after SIV infection was stained with various dilutions of the
Mane-A⁎10 tetramers. Previous titration series showed that the optimal dilution of
tetramer staining for each tetramer was ∼1:500 (not shown).
Table 2
Frequency of tetramer+CD3+CD8+ T cells in SIV-infected pigtail macaques 3 and
14 weeks post-infection.
⁎ Frequency of tetramer+ cells are reported as a percentage of total CD3+CD8+ T cells
with background tetramer FMO values subtracted. Shaded numbers are N0.15%.
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(N0.15% frequency of CD8 T cells) to either or both Tat epitopes by
week 14. All 12 of the SIV infected animals had tetramer+ CD8 T cell
responses speciﬁc for the SIV Gag KP9 epitope by week 14. In contrast,
at 3 weeks after SIV infection, responses to KVA10 and KP9weremuch
more common than responses to KSA10, suggesting that this epitope
is subdominant early in infection. We also studied the avidity of the
KSA10 and KVA10 tetramer binding, in comparison to the KP9
tetramer, to CD8 T cells obtained at week 14 from animal 8240
which had robust responses to all 3 epitopes. The avidity of CD8 Tcells
to all 3 epitopes was similar (Fig. 3).
CD8+ T cells speciﬁc for SIV Tat KVA10 but not KSA10 select for escape
mutations during acute SIV infection
Rhesus macaques that express the Mamu-A⁎01 MHC class I allele
also respond to both a Gag (CM9) and a Tat (SL8) CTL epitope (Allen et
al., 2000). The Tat SL8 epitope, but generally not the Gag CM9 epitope,
undergoes immune escape during acute SIV infection (Price et al.,
2004). Having identiﬁed 2 novel SIV Tat Mane-A⁎10-restricted
epitopes, we sought to determine whether SIV Tat KSA10- and
KVA10-speciﬁc CTL selected for escape mutations at these epitopes
and compared them to the SIV Gag KP9 epitope. To assess putative CTL
escape mutations within SIV Tat KSA10 and KVA10 we ampliﬁed Tat
from plasma viral RNA and sequenced across both epitopes for all
Mane-A⁎10+ animals at multiple timepoints from 2 through to
36 weeks p.i. (Table 3). Multiple non-synonymous mutations within
Tat KVA10 were detected in most Mane-A⁎10+ animals as early as
3 weeks p.i. whereas mutations in Tat KSA10 were not detectable until
at least 12 weeks p.i.. For comparison we also sequenced the same
animals across the immunodominant SIV Gag KP9 epitope for which
we have previously described selection of a speciﬁc CTL escape
mutation (K165R) that exacts a signiﬁcant ﬁtness cost to the virus
(Fernandez et al., 2005). Similar to SIV Tat KSA10, no mutations were
present within SIV Gag KP9 3 weeks p.i., but escape, predominantly to
the K165R variant, was present in most animals by week 20 (Fig. 4).
Several mutations evolved within both SIV Tat KSA10 and KVA10 that
were common to multiple animals although unlike the Gag KP9
epitope therewas no single dominant pattern ofmutation in either Tat
epitope. Nonetheless, it appeared that mutations were somewhat
more uniform within SIV Tat KSA10 than in Tat KVA10. Three
mutations appeared in multiple animals within Tat KSA10 (A89T,A91T and S95P) whereas 5 mutations were detected in Tat KVA10
(K114E, K115E, V118M, E116K and V122M) in multiple animals.
We next examined whether common mutations identiﬁed within
the SIV Tat KSA10 and KVA10 epitopes were in fact CTL escape
mutations. We selected putative CTL escape mutations in both
epitopes which were shared by multiple animals and compared T
cell recognition of variant peptides incorporating these mutations
with wild-type peptides by IFNγ ICS on fresh blood. For SIV Tat KVA10
variant peptides tested there was a signiﬁcant difference in T cell
recognition even at the highest peptide concentration tested between
wild-type KVA10 and variant peptides incorporating common muta-
tions observed in sequencing across the epitope (Fig. 2c). CD8+ T cell
response to wild-type KVA10 peptide was sustained even at low
peptide concentrations (down to 8 ng/ml) while recognition of
variant peptides was completely abrogated indicating that the single
K114E, K115E, V118M and dual K114E and A121E substitutions all
confer escape from SIV Tat KVA10-speciﬁc CD8+ T cells. Analysis of T
cell responses to wild-type SIV Tat KSA10 and variant peptides
incorporating single A89T and A91T substitutions showed that A91T
completely abrogated T cell recognition even at the highest peptide
concentration tested while the A89T substitution had minimal effect
on T cell recognition for all peptide concentrations tested (Fig. 2d).
This suggests that for SIV Tat KSA10, A91T but not A89Tconfers escape
from SIV Tat KSA-speciﬁc CD8+ T cells. We did not detect any
sequence variation within SIV Tat KSA10 and KVA10 epitopes in
several animals not expressing the Mane-A⁎10 allele when plasma
RNA was sequenced 16 to 20 weeks p.i. (data not shown), suggesting
that the mutations observed in Mane-A⁎10+ animals evolved due to
immune selection pressure by SIV Tat-speciﬁc CD8+ T cells.
Complete escape from SIV Tat KVA10-speciﬁc CD8+ T cells during
acute infection
It has been suggested that the rate of CTL escape may be linked to
functional avidity of the CTL response wherein CTL responses which
rapidly select for escapemutations (i.e. acute-phase CTL escape) are of
higher functional avidity than thosewhich select for escapemutations
later in infection (O'Connor et al., 2002b). We therefore assessed the
kinetics and extent of CTL escape within SIV Tat KSA10 and KVA10 in
Mane-A⁎10+ macaque 9021 by cloning SIV Tat from plasma viral RNA
and sequencing individual clones (Table 4). There was a clear
difference between both the rate and extent of CTL escape within
SIV Tat KSA10 and KVA10 epitopes. There was no evidence of CTL
escape in SIV Tat KSA10 until 18 weeks p.i. and even after the
emergence of CTL escape mutations at 18 weeks p.i. wild-type SIV Tat
KSA10 sequence still accounted for at least 25% of the viral
quasispecies out to 36 weeks p.i., the last timepoint tested. By
contrast, CTL escape mutations in SIV Tat KVA10 were detected as
Table 3
Sequence changes across SIV Tat KSA10, Tat KVA10 and Gag KP9 epitopes in Mane-A⁎10+animals.
Animal Week KSA10 Tat epitope Animal Week KVA10 Tat epitope Animal Week KP9 Gag epitope
1.3731 2 KKAKANTSSA 1.3731 2 KKETVEKAVA 1.3731 2 KKFGAEVVP
3 ———————— 3 -EK————— 3 ————————
16 ——————P- 24 ———————— 20 -R——————
24 ——————P- 36 ————————
36 –T———P-
8014 2 KKAKANTSSA 8014 2 KKETVEKAVA 8014 2 KKFGAEVVP
3 NDa 3 ——M——— 3 ————————
16 ———————— 28 -E—————— 20 -R——————
28 ——————P- 36 -E——————
36 ——————P-
8020 2 KKAKANTSSA 8020 2 KKETVEKAVA 8020 2 NDa
3 ———————— 3 ———————— 3 ————————
16 ———————— 18 -T—————— 20 -R——————
28 –T-T——— 28 -T——————
36 –T-T——— 36 -T——————
8240 2 KKAKANTSSA 8240 2 KKETVEKAVA 8240 2 KKFGAEVVP
3 ———————— 3 –K-M—M- 3 ————————
12 ———————— 18 E——————— 20 NDa
28 ——————T- 36 E———————
36 —————PT-
8241 2 KKAKANTSSA 8241 2 KKETVEKAVA 8241 2 KKFGAEVVP
3 NDa 3 -EK-M——— 3 ————————
16 ——T—P- 18 E——————— 20 ———————S
28 ——————P- 36 E———————
36 ——————P-
8244 2 KKAKANTSSA 8244 2 KKETVEKAVA 8244 2 KKFGAEVVP
12 ———————— 3 ——M—M- 3 ————————
28 –T-T——— 18 E——————— 20 -R——————
36 –T-T——— 28 -E——————
36 -E——————
8454 2 KKAKANTSSA 8454 2 KKETVEKAVA 8454 2 KKFGAEVVP
12 ———————— 3 -E—————— 3 ————————
24 ——T——— 12 -E—————— 20 NDa
28 NDa 18 -E——————
9017 2 KKAKANTSSA 9017 2 KKETVEKAVA 9017 2 KKFGAEVVP
3 ———————— 3 –KTA——— 3 ND
28 ———————— 12 ——A——— 20 ND
36 ———————— 18 —————E–
36 E————E–
9020 2 KKAKANTSSA 9020 2 KKETVEKAVA 9020 2 KKFGAEVVP
3 ———————— 3 NDa 3 ————————
28 ———————— 14 -E—————— 20 NDa
36 –T————— 36 NDa
9021 2 KKAKANTSSA 9021 2 KKETVEKAVA 9021 2 KKFGAEVVP
3 ———————— 3 -E—————— 3 ND
14 ———————— 14 -E—————— 20 -R——————
16 –T————— 16 -E——————
20 ——T——— 18 -E————M-
36 ——T——— 28 E—————M-
9175 2 KKAKANTSSA 9175 2 KKETVEKAVA 9175 2 KKFGAEVVP
12 ———————— 28 ———————— 3 ————————
28 –T-T——— 36 ———————— 20 -R——————
36 –V————V
9176 2 KKAKANTSSA 9176 2 KKETVEKAVA 9176 2 KKFGAEVVP
3 NDa 3 ———————— 3 ————————
12 ———————— 18 ———————— 20 ————————
36 ———————— 36 E———————
9183 2 KKAKANTSSA 9183 2 KKETVEKAVA 9183 2 KKFGAEVVP
3 ———————— 3 NDa 3 ————————
28 ———————— 16 E——————— 20 -R——————
36 ———H–P- 36 E———————
Results of bulk PCR sequence analysis including mixed bases.
a Not determined.
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clones sequenced contained CTL escape mutations indicating com-
plete escape from KVA10-speciﬁc CTL.
Discussion
HIV/SIV-speciﬁc CD8+ T cells clearly play a crucial role in
controlling viral replication and an effective HIV vaccine will likely
require generation of CD8+ T cell responses with potent anti-viralactivity (Borrow et al., 1994; Goulder and Watkins, 2008; Jin et al.,
1999; Koup et al., 1994). Although numerous HIV epitopes have been
identiﬁed there are clear differences in the efﬁcacy of CD8+ T cells
speciﬁc for different HIV/SIV protein antigens (Loffredo et al., 2005).
Escape from HIV/SIV-speciﬁc CD8+ T cells frequently undermines
effective control of viral replication (Allen et al., 2000; Barouch et al.,
2002; Borrow et al., 1997; Goulder et al., 1997; O'Connor et al., 2002a;
Phillips et al., 1991). Our group and others have shown that Gag-
speciﬁc CD8+ T cells are more effective at controlling viral replication
Fig. 4. Early immune escape at KVA10 Tat epitope. The proportion of 13 Mane-A⁎10+
animals with wild-type sequence across the SIV Tat epitopes KSA10 and KVA10 and the
SIV Gag epitope KP9 is shown over time after SIV infection. The data is derived from
Table 3; at least 9 of the 13 animals yielded viable sequence at each time point.
WeekN10 refers to multiple time points sequenced between weeks 12–36 p.i..
Table 5
Characteristics of rhesus and pigtail macaque CD8+ T cell epitopes.




Sequence Viral escape detected
(acute/chronic)
Rhesus Mamu-A⁎01 Tat (28–35) STPESANL Acute
Mamu-A⁎01 Gag (181–189) CTPYDINQM Chronic
Pigtail Mane-A⁎10 Tat (87–96) KKAKANTSSA Chronic
Mane-A⁎10 Tat (114–123) KKETVEKAVA Acute
Mane-A⁎10 Gag (164–172) KKFGAEVVP Chronic
320 R.D. Mason et al. / Virology 388 (2009) 315–323than Env-speciﬁc CD8+ T cells (Kiepiela et al., 2007; Peut and Kent,
2009). However, less is known about the utility of CD8+ T cell
responses to SIV regulatory/accessory proteins. We detected CD8+ T
cells targeting a pool of peptides spanning all SIV regulatory/
accessory proteins in most SIV-infected pigtail macaques and found
that Nef and Tat were the most commonly targeted proteins. Further
investigation revealed that SIV Nef-speciﬁc CD8+ T cells targeted a
unique epitope in each Nef responder; however, multiple Tat
responders recognized one of two SIV Tat regions which we mapped
to SIV Tat87–96 (KSA10) and SIV Tat114–123 (KVA10) epitopes. We
subsequently showed that both Tat epitopes are restricted by a
common pigtail macaque MHC class I molecule, Mane-A⁎10, which
also restricts the immunodominant SIV Gag164–172 KP9 CD8+ T cell
epitope (Smith et al., 2005a).
Viral sequencing across both SIV Tat KSA10 and KVA10 epitopes in
Mane-A⁎10+ animals identiﬁed multiple mutations that conferred
escape from CTL recognition. There was a more rapid and complete
shift away from wild-type sequence in SIV Tat KVA10 as compared to
Tat KSA10 or Gag KP9. The occurrence of pigtail macaque SIV Tat and
Gag epitopes restricted by the same high-frequency MHC class I
molecule yet with widely differing escape kinetics mirrors to some
extent the SIV Tat28–35 SL8 and Gag181–189 CM9 responses observed in
Mamu-A⁎01+ rhesus macaques (Table 5) (Allen et al., 2000; BarouchTable 4
Cloning and sequencing across SIV Tat KSA10 and KVA10 epitopes in Mane-A⁎10+
animal 9021.
Week KKETVEKAVA # Clones Week KKAKANTSSA # Clones
2 ———————— 7/7 2 ———————— 7/7





12 ———————— 1/13 12 ———————— 2/2
12 —K———— 1/13
12 –K————— 11/13
14 -E—————— 13/14 14 ———————— 3/3
14 -EK————— 1/14




20 -E—————— 15/17 20 ———————— 5/8





36 ——T——T 1/11et al., 2003; Friedrich et al., 2004a; Loffredo et al., 2007). Although
both Tat SL8- and Gag CM9-speciﬁc CTLs are present at similar
frequencies during acute SIV infection of rhesus macaques, only Tat
SL8-speciﬁc CTL rapidly select for escape mutations during acute
infection (Loffredo et al., 2007; Mothe et al., 2002). We speculate that
the SIV Tat KVA10 response in pigtail macaques is analogous to SIV Tat
SL8 response, whereas the SIV Tat KSA10 response is more analogous
to the SIV Gag KP9 and CM9 responses.
In Mamu-A⁎01+ rhesus macaques, the difference in timing of
escape of CTL epitopes has been linked to the “functional avidity” of
the CTL response wherein CTL responses that drive rapid escape
during acute infection are more potent and effective than those which
select for escape mutations more slowly (O'Connor et al., 2002a). We
found similar avidity for all 3 Mane-A⁎10 restricted epitopes studied.
Acute-phase CD8+ T cell responses rapidly kill virus-infected cells and
facilitate control of virus but emergence of CTL escape mutations in
these epitopes enables virus to persist. Indeed, in rhesus macaques,
Tat SL8-speciﬁc CTLs have been shown to have potent antiviral activity
during acute infection and in vitro studies conﬁrm that Tat SL8-
speciﬁc CTLs are more effective at suppressing viral replication than
Gag CM9-speciﬁc CTL (Loffredo et al., 2005; Mandl et al., 2007).
However, there is little or no ﬁtness cost associated with escape
mutations in Tat SL8 and these mutations persist even inMamu-A⁎01-
animals (Friedrich et al., 2004a; Mandl et al., 2007). By contrast,
mutations in SIV Gag CM9 develop more slowly and are often
accompanied by compensatory mutations in the ﬂanking sequence
and completely revert to wild-type in Mamu-A⁎01-animals (Friedrich
et al., 2004a; Friedrich et al., 2004b; Peyerl et al., 2003). Thus, it
appears that while SIV Tat SL8-speciﬁc CTLs are potent inhibitors of
viral replication during acute infection, Gag CM9-speciﬁc CTLs
facilitate control of viral replication during chronic infection by
targeting a constrained epitope less able to tolerate escape mutations.
The comparative functional proﬁles of these SIV CD8 T cells (either
ability to express multiple cytokines/chemokines or kill virus infected
targets) could also impact upon their ability to select escape
mutations but remains to be determined.
The rapid and complete selection of mutations in SIV Tat KVA10,
which persists through chronic infection, suggests that KVA10
mutations may be well tolerated by the virus and that SIV Tat
KVA10-speciﬁc CD8+ T cells are only effective in controlling wild-type
virus during acute-phase viremia. The KVA10-speciﬁc CTLs commonly
declined later after acute infection, consistent with the early
emergence of escape. By contrast, the slower generation of KSA10-
speciﬁc CTLs and the slow emergence of mutations in SIV Tat KSA10
suggest that this epitope may be subdominant during early infection
but potentially exact a greater ﬁtness cost to viral replication. The
persistence of the A89T mutation at later timepoints despite lack of
signiﬁcant escape from Tat KSA10-speciﬁc CD8+ Tcells is also notable.
Additional studies testing virus with mutated SIV Tat KSA10 or KVA10
sequence in in vitro replication ﬁtness assays or in vivo reversion
studies in Mane-A⁎10 negative animals should further assess the
utility of SIV Tat KSA10- and KVA10-speciﬁc CD8+ T cells. A prediction
from our studies is that the region in Tat targeted by the KSA10
response is more functionally constrained (either within Tat or in the
overlapping reading frames) compared to the KVA10 or SL8 regions of
Tat. This can now be directly analyzed in functional studies by
321R.D. Mason et al. / Virology 388 (2009) 315–323expressing mutated Tat proteins in vitro and assessing their effects on
transcription and other functions of Tat.
The identiﬁcation of 2 novel Mane-A⁎10-restricted SIV Tat
epitopes with distinct CTL escape kinetics will help in evaluating
the effectiveness of individual epitope-speciﬁc CD8+ T cell responses
in HIV/SIV infection. Since the same MHC class I molecule restricts
both epitopes and are located in the same protein, they can be
studied without the confounding effects of MHC restriction, timing
and/or quantity of protein expressed. This is a signiﬁcant advance in
studying CTL responses in pigtail macaques and should provide
further insights into the utility and limitations of SIV-speciﬁc CTLs.
We have previously shown Mane-A⁎10+ macaques have lower viral
loads and delayed SIV disease progression (De Rose et al., 2008a;
Smith et al., 2005b; Smith et al., 2005c) which we postulated was
associated with the immunodominant Mane-A⁎10-restricted SIV Gag
KP9 response. However, since it is now clear that concomitant SIV Tat
KSA10- and KVA10-speciﬁc CD8+ T cell responses are present in
most if not all SIV Gag KP9 responders, and that the mutation
patterns are reasonably uniform, we cannot be certain which of these
responses, or combination or responses, are ultimately responsible
for the improved control of viral replication in Mane-A⁎10+ positive
pigtail macaques. We are currently undertaking additional studies in
Mane-A⁎10+ macaques with viral vector vaccines expressing only
individual SIV Gag KP9, Tat KSA10 and Tat KVA10 epitopes to




Thirty two pigtail macaques (Macaca nemestrina) with SIVmac251
infection examined in this study were part of a peptide-pulsed blood
cell vaccine study (De Rose et al., 2008a). Brieﬂy, the animals were
infected with SIVmac251, placed on antiretroviral therapy from weeks
3–10 and vaccinated with autologous PBMC pulsed with overlapping
15-mer SIV Gag peptides (10 animals), overlapping 15-mer peptides
spanning all SIV proteins (11 animals) at weeks 4, 6, 8 and 10 or
unvaccinated controls (11 animals). The peptides were supplied by
the NIH AIDS reagent repository. All animals were followed for viral
load and disease progression. The SIVmac251 was kindly supplied by
Drs N. Miller and R. Pal (Pal et al., 2002) and injected intravenously at
40 TCID50 as previously described (Batten et al., 2006). Plasma SIV
RNA levels were determined by real-time PCR as previously described
(Dale et al., 2004). All animals in this study had MHC typing for
common MHC I alleles by RSCA as previously described (Pratt et al.,
2006; Smith et al., 2005b). The MHC typing included evaluating
animals for the presence of the Mane-A⁎10 allele which restricts the
immunodominant Gag CD8+ T cell epitope KP9.
Immunological assays
SIV-speciﬁc CD8+ T cell responses were evaluated using
intracellular cytokine staining (ICS) for SIV-speciﬁc expression of
IFNγ following in vitro peptide re-stimulation as previously
described (De Rose et al., 2008a). SIVmac239 and SIVmac251 complete
peptide sets (#6204, 6205, 6207, 6443, 6448, 6449, 6450, 6883 and
8680) were obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH. Brieﬂy, 230 μl whole
blood was incubated with 1 μg/ml/peptide overlapping 15-mer
SIVmac239 peptides or dimethyl suﬂoxide (DMSO) control in the
presence of co-stimulatory antibodies anti-CD28 and anti-CD49d
(both from BD Biosciences/Pharmingen, San Diego CA, USA) and
10 μg/ml Brefeldin A (Sigma, St. Louis MO, USA) for 6 h. Cells were
labeled with anti-CD3 PE (clone SP34-2) and anti-CD8 PerCP (clone
SK1), red blood cells lysed with BD FACS Lysing Solution andremaining leukocytes permeabilized with BD Perm-2 then incubated
with anti-human IFNγ APC (clone B27) (all from BD Biosciences)
and ﬁxed with 1% formaldehyde (Polysciences, Inc Warrington PA,
USA) for FACS analysis.
Tetramer staining
Cryopreserved PBMC were used to stain CD8+ T cells with
tetrameric complexes of the MHC class I protein Mane-A⁎10 folded
around either SIV Gag KP9, SIV Tat KSA10 or SIV Tat KVA10 peptides,
constructed as previously described (Smith et al., 2005c) and kindly
provided by Dr Andrew Brooks. Brieﬂy, PE-conjugated tetramer was
added to 1×106 PBMC and incubated for 30 min at room temperature
before addition of anti-CD3 Paciﬁc blue (clone SP34-2) and anti-CD8
PerCP (clone SK1) (both from BS Biosciences) and a further incubation
for 30 min at room temperature. Excess antibody was removed by
washing cells ﬁrst with FACSwash buffer followed by PBS before ﬁxing
cells with 1% formaldehyde.
Ampliﬁcation of vRNA from plasma
Viral RNA was extracted from cell-plasma using the QIAmp viral
RNA Mini kit (Qiagen) and cDNA prepared from each RNA sample
using SuperScript III reverse transcriptase (Invitrogen) according to
the manufacturer's protocol. Hot Start High-Fidelity DNA Polymerase
(Phusion) was used to amplify Gag and Tat viral sequences from
cDNA by PCR according to manufacturer's protocol. The sense and
antisense oligonucleotides used for PCR ampliﬁcation were 5′-
GAAAGGGGAAGGAGCAG-3′ and 5′-GAAAGGGGAAGGAGCAG-3′ for
t h e Mane - A ⁎ 10 - r e s t r i c t e d Ta t K SA10 ep i t o p e , 5 ′ -
GGCAATTGGTTTGACCTTGCT-3′ and 5′-CTTGTGGAAAGTCCCTGCTG-3′
for the Mane-A⁎10-restricted Tat KVA10 epitope and 5′-CACGCAGAA-
GAGAAAGTGAA-3′ and 5′-GTTCCTGCAATRTCKGAT-3′ for Mane-A⁎10-
restrictedGag KP9 epitope. The following cycling conditionswere used
for each ampliﬁcation: 98 °C for 30 s followed by 40 cycles of 98 °C for
10 s, 58 °C for 15 s, and 72 °C for 1min,with a ﬁnal extension of 72°C for
10 min. The ﬁnal PCR products were analyzed by 1% agarose gel
electrophoresis and corresponding bands excised and puriﬁed using
Qiagen gel puriﬁcation.
Viral sequencing
SIV Gag and Tat PCR fragments were gel puriﬁed (Qiagen) and used
for sequencing of bulk PCR products on an ABI3130xl genetic analyzer
automated sequencer as previously described (Loh et al., 2007). For
analysis of individual cloned viral sequences, gel puriﬁed amplicons
were cloned into pGEM-T Easy Vector (Promega) and direct sequen-
cing of individual bacterial colonies was performed. Brieﬂy, a single
bacterial colony (∼2 mm) was transferred to 15 μl distilled water and
resuspended by pipeting. The cell suspensionwas then heated at 92 °C
for 15 min and used as template for direct sequencing (Peut and Kent,
2007). Chromatograms were carefully inspected using ContigExpress
(Invitrogen).
Data analysis
Flow cytometric data was analyzed with FloJo software version
7.2.2 (Tree Star Inc, Ashland OR, USA). Background DMSO or tetramer
FMO subtraction was performed for all SIV-speciﬁc responses
reported.
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